Phyton Biotech Acquires Assets of Natural Pharmaceuticals, Inc.

October 12, 2009 (SAN ANTONIO, TX) -- Phyton Biotech, LLC (Phyton), an affiliate of Phyton, Inc., today announced that it has purchased the assets of Natural Pharmaceuticals, Inc. (NPI), a leading manufacturer of oncology drug active pharmaceutical ingredients (API's).

Under the terms of the agreement, Phyton will acquire assets of NPI, which include intellectual property and patents for the production of taxane API's, a fully-staffed cGMP manufacturing facility in Delta, BC, Canada, and an API manufacturing subsidiary in Shanghai, China, Syntax Biotechnology, LTD. Phyton will be contributing sufficient capital to sustain and grow the business as well as management oversight for the new company. Other deal terms were not disclosed.

The new organization will unite Phyton affiliate, Phyton Biotech GmbH, the world's largest cGMP plant cell fermentation facility dedicated to primary taxane production with NPI's proprietary downstream synthesis of paclitaxel, docetaxel, and additional API's.

According to Phyton President, Paul Johnson, "NPI is a well-known player in the global taxane API market. The synergies from combining both NPI and Phyton's proprietary and patented technologies were very apparent to us and will make the new organization a solid force in the taxane API market."

Dr. Roland R. Franke, CEO of NPI comments that, ""The fusion with NPI makes Phyton Biotech the world's only API company that can produce semi-synthetic taxanes without depending on biomass from tree plantations. The combination of plant cell fermentation and innovative manufacturing technology creates enormous capacity up front, and limitless future potential in the world-wide taxane API market."

Near term, the company will focus on integrating NPI and Phyton from infrastructure and organizational standpoints, along with increasing the output of paclitaxel and docetaxel API's to meet the growing market demand.

About Phyton
Phyton, Inc., an affiliate of DFB Pharmaceuticals, Inc, will operate Phyton Biotech LLC, and operates Phyton Biotech GmbH, a world leader in proprietary plant cell culture technology for research and commercial production of API's. Its manufacturing facility, located in Ahrensburg, Germany, is the world's largest cGMP plant cell culture facility with bioreactors up to 75m3. It is specifically designed to grow plant cells in culture via patented processes, carry out all related QA/QC activities, and conduct development work such as pre-fermentation and scale up. For more information about Phyton Biotech, visit: www.phytonbiotech.com.

About NPI
Natural Pharmaceuticals, Inc. (NPI) is a global source for high-purity semi-synthetic taxane API's. Founded in 1998, NPI produces a sustainable supply of semi-synthetic paclitaxel API for clinical research and commercial purposes via a unique and patented process. NPI additionally produces non-infringing docetaxel API for development purposes via a patented process. With a production facility in Delta, BC, Canada, and manufacturing subsidiary in Shanghai, China, NPI is headquartered in Massachusetts.

Contact: Doug Leaffer
Phyton Biotech, LLC
+1-978-524-8586